Study maps potential route to effective dengue vaccines

January 18, 2016 by Christopher Packham report
A TEM micrograph showing Dengue virus virions (the cluster of dark dots near the center). Image: CDC

(Medical Xpress)—The mosquito-borne dengue virus infects up to 390 million people a year. Symptoms of dengue fever include a measles-like rash, fever, body aches and joint pain. In a small subset of cases, the disease develops into life-threatening dengue hemorrhagic fever, resulting in bleeding and low platelet count; this can progress to dengue shock syndrome, which manifests as dangerously low blood pressure.

There are four dengue virus serotypes, DENV1-4. The risk factors for developing disease include exposure to a heterologous DENV serotype, the specific infecting strains, the interval of time between infections, age, ethnicity, genetics, and others. Neutralizing antibodies (NAbs) are believed to provide long-term protection against infection and the development of severe forms of dengue.

The goal of researchers is to produce dengue vaccines that provide protection against all DENV serotypes, but vaccine development is inhibited by a lack of knowledge about the association of homotypic and heterotypic NAb titers. A group of researchers from Nicaragua, the U.S. and the U.K. have collaborated on a study into the correlation between antibody titers and protection from symptomatic infection. They have published their results in the Proceedings of the National Academy of Sciences.

The researchers analyzed data from the Nicaraguan Pediatric Dengue Cohort Study (2004 to present), described as a community-based study featuring passive surveillance with an active cohort of ~3500 children aged two to 14. Data was culled from healthy annual blood samples; symptomatic dengue infections were confirmed in children who presented to the health center with suspected dengue.

Using the data to reconstruct the immunological histories for each child, the authors analyzed the results and concluded that higher preinfection neutralizing antibody titers correlate with a lower probability of symptomatic infections in children. They also determined that levels 0f cross-reactive neutralizing antibodies are maintained in healthy children over a long period of time, possibly due to re-exposure.

The authors write, "We observed that a higher median preinfection NAb titer or NAb titer to the 2° infecting serotype, but not the NAb titer to the 1° serotype, was significantly associated with reduced probability of 2° symptomatic DENV infection, indicating that cross-reactive NAbs determine protection, as others have proposed."

The researchers also found by tightening or loosening their own criteria for inapparent infections that the protective effect of preinfection NAbs remained. In addition to determining that higher levels of cross-reactive preinfection NAbs likely confer reduced probability of developing symptomatic , they also believe that in endemic settings, NAb titers do not become increasingly type-specific.

The study also suggests that the major independent predictor of symptomatic infection is epidemic force, and that age and the time between 1° and 2° infections were lesser predictors. While this contrasts with the results of previous studies, the authors note that those studies used age and the years between infections as indirect measures of NAb titers, while the current study directly observes the effect of NAb titers on infection outcomes.

They write, "Our findings have potential implications for vaccine development and implementation. Vaccines that generate higher levels of NAb titers will potentially reduce the probability of symptomatic infection, but the level of NAbs required for protection against symptomatic disease may differ from year to year in endemic settings."

Explore further: Study could lead to vaccines and treatment for dengue virus

More information: Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. PNAS 2016 ; published ahead of print January 4, 2016, DOI: 10.1073/pnas.1522136113

The four dengue virus serotypes (DENV1–4) are mosquito-borne flaviviruses that infect ∼390 million people annually; up to 100 million infections are symptomatic, and 500,000 cases progress to severe disease. Exposure to a heterologous DENV serotype, the specific infecting DENV strains, and the interval of time between infections, as well as age, ethnicity, genetic polymorphisms, and comorbidities of the host, are all risk factors for severe dengue. In contrast, neutralizing antibodies (NAbs) are thought to provide long-lived protection against symptomatic infection and severe dengue. The objective of dengue vaccines is to provide balanced protection against all DENV serotypes simultaneously. However, the association between homotypic and heterotypic NAb titers and protection against symptomatic infection remains poorly understood. Here, we demonstrate that the titer of preinfection cross-reactive NAbs correlates with reduced likelihood of symptomatic secondary infection in a longitudinal pediatric dengue cohort in Nicaragua. The protective effect of NAb titers on infection outcome remained significant when controlled for age, number of years between infections, and epidemic force, as well as with relaxed or more stringent criteria for defining inapparent DENV infections. Further, individuals with higher NAb titers immediately after primary infection had delayed symptomatic infections compared with those with lower titers. However, overall NAb titers increased modestly in magnitude and remained serotype cross-reactive in the years between infections, possibly due to reexposure. These findings establish that anti-DENV NAb titers correlate with reduced probability of symptomatic DENV infection and provide insights into longitudinal characteristics of antibody-mediated immunity to DENV in an endemic setting.

Related Stories

Study could lead to vaccines and treatment for dengue virus

July 2, 2015

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue ...

Dengue vaccine enters phase 3 trial in Brazil

January 14, 2016

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen ...

Human antibody for dengue virus isolated

June 22, 2012

( -- A group of scientists in Singapore and the UK have isolated a human antibody capable of effectively neutralizing the mosquito-borne dengue virus. Dengue fever is currently incurable and infects an estimated ...

Global consortium rewrites the 'cartography' of dengue virus

September 17, 2015

An international consortium of laboratories worldwide that are studying the differences among dengue viruses has shown that while the long-held view that there are four genetically-distinct types of the virus holds, far more ...

Recommended for you

Macrophages shown to be essential to a healthy heart rhythm

April 20, 2017

A Massachusetts General Hospital (MGH)-led research team has identified a surprising new role for macrophages, the white blood cells primarily known for removing pathogens, cellular debris and other unwanted materials. In ...

Gut bacteria affect ageing

April 19, 2017

It loses its pigments, its motor skills and mental faculties decline, it gets cancer – the turquoise killifish (Nothobranchius furzeri) struggles with the same signs of old age that affect many other living creatures. Researchers ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.